In the recent years, organometallic compounds have become recognized as promising anti-cancer drug candidates. While radioactive 186/188 Re compounds are already used in clinics for cancer treatment, cold Re organometallic compounds have mostly been explored as luminescent probes and photosensitizers in photo-catalysis. However, a growing number of studies have recently revealed the potential of Re organometallic complexes as anticancer agents.
INTRODUCTION
Despite the growing body of research, cancer remains among the leading causes of death in the world, in particular in high-income countries (although cancer rates are increasing in lowerincome countries which already account for 70% of world cancer deaths). 1 The survival rates hugely vary with the type and stage of tumor, as well as age, sex and socio-economic situation of each patient.
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For example, about 50% of adult (15- However, while patients with testicular cancer, melanoma, prostate cancer and Hodgkin lymphoma have a ten-year survival rate of over 80%, less than 15% of patients with pancreas, lung, brain, esophagus and stomach cancers survive that long. 2 Cancer treatment depends on the type, stage and location of tumor, but most patients undergo chemotherapy either as the main treatment or in combination with surgery and/or radiotherapy. Over 50% of tumors are treated with platinum-based drugs (cisplatin, carboplatin, oxaliplatin) alone or co-administered with other chemotherapeutic agents. 3 Nevertheless, new anti-cancer drugs are still being actively sought due to the emergence of platinium resistance and the severe side effects associated with the chemotherapic treatments. 4 In the last decades, many organometallic compounds (i.e. compounds containing at least one metal-carbon bond) have proven themselves as extremely promising anti-cancer drug candidates.
5-14
Organometallic complexes offer structural and stereochemical variety, 15, 16 the possibility of rational ligand design, and diverse mechanisms of action (e.g. via redox activity, ligand exchange, catalytic activity and/or photo-activity). 17 18-21 Compared with some intensively investigated organometallic complexes such as those based on ruthenium, 12, 13 relatively few examples of cytotoxic rhenium organometallic compounds are found in the literature. However, numerous studies have been recently reported describing the potential of such compounds. Indeed, Re organometallic compounds possess several intrinsic properties advantageous for the development of novel anti-cancer drug candidates. For instance, many Re organometallic complexes are excellent luminescent probes with long-lived emission states, large Stokes shifts, high quantum yields and emission that can be tuned by varying the ligands. 37, 48 They can thus be easily followed inside cells by conventional and/or time-resolved (e.g. FLIMS) emission microscopy to elucidate their cellular distribution and mechanism of action. Furthermore, all reported cytotoxic Re organometallic compounds are based on the Re(CO) 3 core, which is chemically robust and easily accessible, e.g. from [Re(CO) 3 29, 34 Re(CO) 5 Cl/Re(CO) 5 Br 26-28, 31-33, 41, 42, 49 or Re 2 (CO) 10 24, 30, 40 in 1-3 step synthesis. The introduced ligands can be designed to incorporate other functional moieties such as targeting biomolecules. 28, 29, 34, 35, 39, 41, 44, 46, 47, 50, 51 However, the key property of the Re organometallic complexes is the possibility to prepare "hot" analogues that can be applied for radio-imaging as well as for therapy . Besides   186   Re and   188   Re isotopes,   99m Tc can often be used with the same set of ligands as the cold Re due to the similarity in the coordination chemistry of these group 7 congeners. [52] [53] [54] [55] Thus, a Re complex has the potential to be a multimodal molecule, which acts as a luminescent probe, a radio-imaging and a pharmaceutical agent.
Importantly, "hot" analogues can be used to run in vivo biodistribution and pharmacokinetics studies, which are crucial for the development of new drugs.
In this review, we present the cytotoxic Re organometallic complexes that have been reported in the literature to date. Their modes of cytotoxic action, when known, are discussed in detail.
The compounds presented in this review are categorized into two main groups according to the nature of their anti-proliferative activity, namely "traditional" cytotoxicity and photo-toxicity.
Anti-cancer and other therapeutic applications of radio-pharmaceuticals based on 186/188 Re have been extensively described in several excellent reviews. 54, [56] [57] [58] [59] Since some of them are extremely recent, this topic is not discussed herein. Of note, two relatively recent and comprehensive reviews by Lo et al. 37 and Coogan et al. 48 have discussed the cellular uptake, localization and cytotoxicity of luminescent Re(I) organometallic complexes, but both are more focused on imaging applications and do not cover non luminescent organometallic Re compounds. As can been seen in these reviews, several Re complexes have been reported to interact with DNA and/or proteins, yet not all of them have been screened for cytotoxicity. Here we discuss only the Re organometallic compounds that have been studied in cell culture. The cytotoxicity of several bipyridine and phenantroline based Re(I) complexes ( Figure 1A and B, 1-14) have been reported. Their anti-proliferative activity reached or even exceeded the one of cisplatin on various human cancer cell lines. 28, 30, 32, 39, 40, 45, 49, 51 The cytotoxicity of the compounds generally increased with lipophilicity, 32, 33, 39, 49, 51 most probably due to an improved cellular uptake. Re(I) complexes 9 ( Figure 1A ) derivatized with a fluorous pendant were the only exception to this trend. Their cytotoxicity diminished with rising lipophilicity. 39 However, these compounds are exceptionally lipophilic (logP o/w in the range of 5 to 9) and could form self-aggregates due to favorable F-F interactions. The uptake of anti-proliferative Re(I) tricarbonyl bisimine complexes is often very fast and efficient, yet little is known about their mechanism. Some cytotoxic cationic complexes such as 1a-c appear to accumulate in cells via passive diffusion. 49 Re luminescent probes used to sense Cd(II) and Zn(II) (5 on Figure 1A) are, however, taken up via an energy-dependent pathway such as endocytosis as demonstrated by temperature and ATP production inhibition uptake assays. 32 Interestingly, fluorescence microscopy cellular localization studies have never -to the best of our knowledge -identified a cytotoxic Re(I) tricarbonyl bisimine complex located inside the nucleus. All compounds screened for cytotoxicity were indeed imaged in the cytoplasm. 28, 32, 33, 39, 51 When co-localization experiments were performed on Re organometallic complexes 7i and 9f ( Figure 1A ), predominately mitochondrial (up to 80%) localization was reported. 39 A non-negligible percentage of endosomal accumulation (about 20%) has also been detected for compound 7i 39 As a note of caution, although fluorescent microscopy imaging is an important tool in the investigation of the cellular behavior of Re organometallic complexes, their luminescence can sometimes be quenched in cells. 39, 44, 47 Due to this problem, direct measurements of Re content by inductively coupled plasma mass spectrometry (ICP-MS) or atomic absorption spectroscopy (AAS) 60 can be a more accurate method to quantify the cellular uptake and distribution of Re complexes.
CYTOTOXIC Re ORGANOMETALLIC COMPLEXES
The first cytotoxic bisimine Re complex (15 on Figure 1B ) with anti-proliferative properties, however, was in some ways an exception to the typical photo-physical and biological properties of these compounds. Based on a pyridine-triazine ligand (2-amino-4-phenylamino-6-(2-pyridyl)-1,3,5-triazine), compound 15 emitted only in the solid state and was designed in a crescent shape to fit the major or minor grooves of DNA. Another Re(I) tricarbonyl diimine compound using neither bipyridine nor phenathroline, but asymmetric azines (16 on Figure 1B ) as bidentate ligands have been reported to be active on human neuroblastoma NB69, glioblastoma astrocytoma U373, breast cancer MRC-7 (hormoneresponsive) and EVSA-T (hormone-independent) with IC 50 in the 4-10 M range. 31 Some azines are known to possess some anti-cancer activity on their own, but their cytotoxicity was increased by coordination to the Re center. Curiously, Re(CO) 5 Cl displayed the same activity as Re(I) azines, while Re(CO) 5 Br failed to produce a strong anti-proliferative effect on U2OS (osteosarcoma, >100 M), HepG2 (>100 M) and MCF-7 (57 M) in a different study. 44 Although a substantial number of Re(I) tricarbonyl bisimine complexes 
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One of such derivatives has been used to image transplanted neural stem and progenitor cells in a SPECT/CT study on mice. 68 As already discussed for Re bisimine compounds above, despite the favorable photophysical properties of certain Re organometallic complexes, emission microscopy localization is not 
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Designed with the cisplatin ligand exchange-based mechanism of action in mind, this type of complexes has labile alkoxy/hydroxyl ligands. The dppf ligand of the Re compounds 31 and 32 ( Figure 4 ) can also be released/exchanged and contributes to the overall cytotoxic effect, as dppf has been reported to be toxic on its own. 72, 73 Re(I) alkoxo/hydroxo compounds have been screened on over ten different human and murine tumor cell lines. These complexes were generally very active against suspended cancer cell cultures. However, on solid tumor cells, their cytotoxicity significantly varied with each particular cell line. The mechanism of toxicity has been described in considerable detail for compounds 30-31.
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The alkoxo/hydroxo Re(I) carbonyl compounds are able to cause DNA strand scission and severely affect the nucleic acid metabolism via enzymes such as dihydrofolate reductase, PRPP-amido transferase and thymidine kinase. Their mode of action was not explored, but enhanced cellular growth at lower concentration was explained in terms of the "heavy atom" effect on the estrogen receptor that has been previously described for Cd. 74, 75 Semicarbazones were used as ligands in Re compounds 37 Figure 6 ) have been tested on HT 29 (colorectal cancer), MCF-7 (hormone-dependent breast cancer), A549S (lung adenocarcinoma) and HeLa (solid uterine carcinoma). 38 Curiously, these compounds also possessed a particularly high activity (4 M) against MCF-7 breast cancer cells, while being only moderately or essentially non-toxic to other cell lines. This property has been further explored in the course of an in vivo study on MCF-7 tumor bearing mice. 41 In this work, the treatment with Re organometallic complex 40b was combined with cisplatin and Gd(III) administration, since both inorganic Re/cisplatin and Gd/cisplatin co-administration studies had previously shown synergetic action between cisplatin/Re and cisplatin/Gd(III) compounds, respectively. The intraperitoneal cisplatin administration (2 per week, 3 mg/kg) combined with oral daily (5/7 days/week) administration of a Gd complex ((tetrakis(1-octanol) tris(5-aminosalicylate) Gd(III)) and Re(CO) 3 (Se-Se)Cl (40b) led to 50% tumor volume reduction after 3 weeks treatment. By comparison, only 25% tumor volume reduction was observed for mice treated with cisplatin only. However, no control groups were treated with Re or Gd compound only, so the extent of complex 40b contribution to tumor reduction has not been directly assessed. The largest effect on tumor volume was achieved using the maxim dose of Gd (100 mg/kg) and the minimal dose of Re (10 mg/kg). In the mice treated with higher doses of Re, more deaths were observed. Tc(CO) 3 Cp moiety was conjugated to atriaryl butane skeleton of tamoxifen via an amide bond. 78 Recently, the Re(CO) 3 core has been conjugated to sulfonamide moieties to target human carbonic anhydrases (hCAs), which have emerged as an interesting target for therapy and diagnosis due to their overexpression induced by hypoxia in cancer cells. [79] [80] [81] High concentration of carbonic acid resulting from this excessive activity of hCAs leads to a pronounced decrease in extracellular pH (down to ca. 6 instead of 7.4).
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Re complexes (43-46, Figure 7 ) have been shown to be excellent hCA inhibitors with submicromolar affinities and interesting selectivity profiles for various hCA isoforms. 76, 82 No IC 
PHOTO-TOXIC Re ORGANOMETALLIC COMPLEXES
Very few photo-toxic Re organometallic compounds have been identified to date (Figure 8) . 43, 44, 46, 47 Most of them act as photodynamic therapy (PDT) photosensitizers (PS) -i.e. they transfer the energy received from light to oxygen (present in tissues) to generate reactive oxygen species (ROS). A PS excited by irradiation undergoes two types of reactions. 83 In the so-called type I reaction, the PS directly interacts with a substrate (e.g. cell membrane, protein) to form radicals or radical ions, which can in turn interact with oxygen to produce the highly reactive singlet oxygen. The type II reaction is defined as generation of singlet oxygen via PS-oxygen interaction. 83 Although many more Re compounds have been identified as efficient triplet photosensitizers, 39, [84] [85] [86] [87] [88] this property has been more applied in photo-catalysis than in anti-cancer drug development.
The shown to greatly increase their cytotoxicity (from >100 M to 3 M IC 50 ) upon 590-700 nm light irradiation. 46 However, the light activity of these compounds originated entirely from the porphyrin moiety as the Re complex present in the conjugate does not produce any singlet oxygen upon irradiation at 590-700 nm. The Re conjugation, however, was found to improve the uptake of these porphyrin-Re conjugates. Hot 
CONCLUSIONS AND PERSPECTIVES
In 
